KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) FCF Margin: 2010-2025

Historic FCF Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -414.55%.

  • Nektar Therapeutics' FCF Margin fell 22968.00% to -414.55% in Q3 2025 from the same period last year, while for Sep 2025 it was -304.08%, marking a year-over-year decrease of 11316.00%. This contributed to the annual value of -180.01% for FY2024, which is 3467.00% up from last year.
  • Nektar Therapeutics' FCF Margin amounted to -414.55% in Q3 2025, which was down 1.20% from -409.62% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' FCF Margin registered a high of -159.88% during Q4 2024, and its lowest value of -629.51% during Q4 2021.
  • For the 3-year period, Nektar Therapeutics' FCF Margin averaged around -262.58%, with its median value being -222.03% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first spiked by 36,517bps in 2022, then tumbled by 24,832bps in 2025.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' FCF Margin stood at -629.51% in 2021, then surged by 36,517bps to -264.34% in 2022, then spiked by 6,637bps to -197.97% in 2023, then spiked by 3,808bps to -159.88% in 2024, then tumbled by 22,968bps to -414.55% in 2025.
  • Its FCF Margin stands at -414.55% for Q3 2025, versus -409.62% for Q2 2025 and -468.98% for Q1 2025.